Aethlon Medical Announces Receipt of U.S. Patent Protecting Methods of Capturing MHC-Antigen-Associated Exosomes

On July 19, 2017, Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced that the United States Patent and Trademark Office has granted U.S. Patent Number 9,707,333 (the '333 Patent), entitled "EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES." The '333 Patent covers methods of capturing exosomes that include an MHC-I or MHC-II antigen, whereby a patient suspected of receiving a benefit from exosome capture and removal is selected, and the whole blood, plasma, or serum from the patient is contacted with a substrate that includes antibodies specific for an MHC-I or MHC-II antigen. The '333 Patent also covers methods of capturing and removing MHC-I or MHC-II antigen-associated exosomes from whole blood, plasma, or serum of a patient, and returning the whole blood, plasma, or serum to the patient with substantially fewer MHC-I or MHC-II antigen-associated exosomes. MHC-I and MHC-II antigen-associated exosomes contribute to the progression of numerous disease conditions, including cancer, autoimmune disorders, and neurodegenerative diseases. The '333 Patent is a continuation of U.S. Patent Number 9,364,601, which covers methods of lectin-based capture of exosomes from a patient, and U.S. Patent Number 8,288,172, which protects the use of the Aethlon Hemopurifier® in a method to remove immunosuppressive exosomes from blood.
Login Or Register To Read Full Story